Clostridioides Difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, or Prevention
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Clostridioides difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, or Prevention." The purpose of this guidance is to assist sponsors in the clinical development of drugs to support an indication of treatment, reduction of recurrence, or prevention of Clostridioides difficile infection (CDI). This guidance finalizes the draft guidance titled "Clostridioides difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, and Prevention" issued on October 28. 2022.
Official guideline text: FDA ↗
Brief written by VigiEye from the company's press release. Claims are the company's own. AI-assisted; check the source before acting.
RegulatoryCompany releaseBeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
RegulatoryCompany releaseImricor starts US launch of NorthStar iMR system after paediatric FDA clearances
RegulatoryCompany releaseBeyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
RegulatoryCompany releaseFDA sets 10 March 2027 goal date for Intellia's one-time hereditary angioedema gene-editing therapy
RegulatoryCompany releaseBeyondSpring wins FDA Fast Track for plinabulin plus docetaxel in post-immunotherapy NSCLC
RegulatoryCompany release